Please login to the form below

Not currently logged in
Email:
Password:

Shire wins EU licence for pancreatic cancer drug Onivyde

Combination treatment is the first approved for this patient population

ShireThe European Commission has approved Shire's Onivyde for the treatment of adults with metastatic adenocarcinoma of the pancreas, making it the first licensed treatment for this patient group in the EU.

Authorised as a second-line combination therapy, Onivyde (pegylated liposomal irinotecan hydrochloride trihydrate) will be administered with 5-fluorouracil (5-FU) and leucovorin (LV) in adult patients who have progressed following treatment with Lilly's Gemzar (gemcitabine).

The EU licensing follows FDA approval of the drug, after Shire won US marketing authorisation in October last year.

Data from the phase III trial NAPOLI-1 showed that the triple-drug treatment significantly extended overall survival at an average of 6.1 months compared to 4.2 months for the 5-FU and LV-only group.

As such Onivyde marks a first for this indication of pancreatic cancer patients for whom there has been little improvement in prognosis over the last twenty years.

Dr Philip Vickers, global head of R&D at Shire, commented: “The approval of Onivyde marks a significant step forward in Shire's focus to develop and commercialise treatments that represent the most promising science in oncology.”

Pancreatic cancer is the fourth leading cause of cancer death in Europe and seventh worldwide, with typically poor prognosis and an estimated 330,400 deaths each year.

The global pancreatic cancer market has seen rapid growth in recent years and is forecast to reach worldwide sales of $1.6bn by 2017, with the majority of sales attributed to Celgene's Abraxane (paclitaxel) in combination with Gemzar.

Article by
Rebecca Clifford

18th October 2016

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics